Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Intellia Therapeutics, Inc. | ntla-10k_20171231.htm |
| EX-32.1 - EX-32.1 - Intellia Therapeutics, Inc. | ntla-ex321_6.htm |
| EX-31.2 - EX-31.2 - Intellia Therapeutics, Inc. | ntla-ex312_7.htm |
| EX-31.1 - EX-31.1 - Intellia Therapeutics, Inc. | ntla-ex311_8.htm |
| EX-21.1 - EX-21.1 - Intellia Therapeutics, Inc. | ntla-ex211_373.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-218508 on Form S-3 and Registration Statement Nos. 333-218511 and 333-211200 on Form S-8 of our report dated March 14, 2018, relating to the consolidated financial statements of Intellia Therapeutics, Inc. appearing in this Annual Report on Form 10-K of Intellia Therapeutics, Inc. for the year ended December 31, 2017.
|
/s/ Deloitte & Touche LLP |
|
|
|
|
|
Boston, Massachusetts |
|
|
March 14, 2018 |
|